-
Product Insights
NewNet Present Value Model: SanBio Co Ltd’s Vandefitemcel
Empower your strategies with our Net Present Value Model: SanBio Co Ltd's Vandefitemcel report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BGC-0228 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BGC-0228 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BGC-0228 in Gastric Cancer Drug Details: BGC-0228 is under development for...
-
Product Insights
NewNet Present Value Model: SanBio Co Ltd’s SB-623
Empower your strategies with our Net Present Value Model: SanBio Co Ltd's SB-623 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of SanBio Co Ltd Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of SanBio Co Ltd Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewOptic Neuritis – Drugs In Development, 2024
Empower your strategies with our Optic Neuritis – Drugs In Development, 2024 report and make more profitable business decisions. Optic neuritis is an inflammation of the optic nerve, the bundle of nerve fibers that transmits visual information from the eye to the brain. Symptoms include pain, vision loss, dyschromatopsia, Uhthoff’s phenomenon, and flashing lights. Risk factors include age and genetic mutations. The Optic Neuritis drugs in development market research report provide comprehensive information on the therapeutics under development for Optic Neuritis,...
-
Product Insights
NewPeripheral Nerve Injury – Drugs In Development, 2024
Empower your strategies with our Peripheral Nerve Injury – Drugs In Development, 2024 report and make more profitable business decisions. Peripheral nerve injuries pose various challenges to patients, ranging from mild discomfort to life-long impairment. Peripheral nerve injuries include brachial plexus injury, peroneal nerve injury (foot drop), and spinal accessory nerve injury. The Peripheral Nerve Injury drugs in development market research report provide comprehensive information on the therapeutics under development for Peripheral Nerve Injury, complete with analysis by stage of development,...
-
Product Insights
NewDown Syndrome – Drugs In Development, 2024
Empower your strategies with our Down Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Down syndrome is a genetic disorder that causes lifelong mental retardation, developmental delays, and other problems. Down syndrome varies in severity, so developmental problems range from moderate to serious. Children with Down syndrome have a distinct facial appearance. Though not all children with Down syndrome have the same features, some of the more common features are flattened facial features, small head, short...
-
Product Insights
NewMuscular Dystrophy – Drugs In Development, 2024
Empower your strategies with our Muscular Dystrophy – Drugs In Development, 2024 report and make more profitable business decisions. Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness, and progressive difficulty walking. The Muscular Dystrophy drugs in development market research report provide comprehensive information on...
-
Product Insights
NewRetinitis Pigmentosa (Retinitis) – Drugs In Development, 2024
Empower your strategies with our Retinitis Pigmentosa (Retinitis) – Drugs In Development, 2024 report and make more profitable business decisions. Retinitis pigmentosa refers to a group of diseases that cause a slow but progressive loss of vision. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance. The Retinitis Pigmentosa (Retinitis) drugs in development market research report provide comprehensive information on...